FDA approves Merck’s bladder cancer drug
24 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved two new indications for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for bladder cancer...
List view / Grid view
24 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved two new indications for Merck’s Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for bladder cancer...
23 May 2017 | By Niamh Marriott, Junior Editor
Grifols now provides European countries accepting products with the CE marking with a test to detect the presence of the Zika virus in donated blood.
23 May 2017 | By Niamh Marriott, Junior Editor
The State Patent Bureau of the Republic of Lithuania (SPB) and Kaunas University of Technology National Innovation and Entrepreneurship Centre (KTU NIEC) has signed the collaboration agreement, which laid foundation for the new Patent Library – PATLIB Centre. This will be the first time, when a PATLIB Centre is established…
23 May 2017 | By Niamh Marriott, Junior Editor
Biosimilar medicines have dramatically increased patient access to biological medicines, according to the recently published QuintilesIMS report...
22 May 2017 | By Niamh Marriott, Junior Editor
Approximately one in four adults prescribed an antibiotic in an outpatient setting for community-acquired pneumonia does not respond to treatment...
22 May 2017 | By Niamh Marriott, Junior Editor
Pfizer have announced an extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive...
22 May 2017 | By Niamh Marriott, Junior Editor
Bonesupport, the Scandinavian medical technology company, has enrolled their first patient at the University of Texas Health Science Center at San Antonio into the company’s pivotal Investigational Device Exemption (IDE) trial. Cerament G is an injectable antibiotic-eluting bone graft substitute that has proven remodelling capabilities and provides local sustained delivery…
22 May 2017 | By Niamh Marriott, Junior Editor
The first high energy proton beam therapy system to be installed in the UK has arrived at The Rutherford Cancer Centre, South Wales.
19 May 2017 | By Tecan
Tecan’s popular Infinite® 200 PRO series of multimode microplate readers has been updated to even better serve the life sciences market, with a number of new options and configurations designed to provide flexible and user-friendly solutions for entry level research applications...
19 May 2017 | By Sarah Wills, Editorial Assistant: European Pharmaceutical Review
While there have been improvements in some areas of cancer prevention and early detection, the use of potentially lifesaving measures is suboptimal and strongly influenced by individual behaviours, as well as social, economic, and public policy factors, according to a new report from the American Cancer Society.
19 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
Intellectual Property (IP) could be considered the foundation for pharmaceutical innovation. In healthcare, innovation means improved health outcomes: avoiding illness; slowing disease progression; improving patients’ lives; and reducing overall costs for healthcare systems. With over 80 medicines approved every year – including some 30 new, approved substances – and over…
19 May 2017 | By Niamh Marriott, Junior Editor
A diagnostic MRI followed by one of three MRI-guided biopsy strategies is a cost-effective method to detect prostate cancer, according to a new study...
18 May 2017 | By The Optical Society
Diamonds are renowned for their exquisite beauty and unrivalled durability, but they also are highly prized by scientists and engineers for their exceptional optical and physical properties. In a first-of-its-kind demonstration of diamond’s promising technological applications, a team of engineers from Harvard University has developed a new class of Raman…
18 May 2017 | By American Institute of Physics (AIP)
Cancer screening is a critical approach for preventing cancer deaths because cases caught early are often more treatable. But while there are already existing ways to screen for different types of cancer, there is a great need for even more safe, cheap and effective methods to save even more lives.…
18 May 2017 | By Phillip Godden, CEO, Protak Scientific
Enzyme Indicators (EI’s) are an industry-changing advance in measuring decontamination performance. No longer will the pharmaceutical industry suffer financial losses, wasted man hours, and the burden of high risks associated with BI’s.